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THE AIDS PROJECT 
48 Deering Street, Portland. Maine 04101 
Press Release 
DATE: February 11, 1988 CONTACT: Robert Mitchell 
Executive Director 
PORTLAND PREMIERES MOVIE ON FAMILIES OF AIDS PATIENTS 
PORTLAND The Portland premiere of Too Little, Too Late, 
a powerful new video documentary about families of AIDS 
patients, will be held on Saturday, February 27,_ 1988, at 
the Luther Bonney Auditorium, University of Southern Maine 
campus, Portland. There will be two showings, one at 7PM 
and one at 8:30PM. 
Too Little, Too Late was inspired by Barbara Peabody's 
highly acclaimed book, The Screaming Room, a moving account 
of the author's love, dedication and courage in caring for 
her 28 year old son during the last 10 months of his life. 
Barbara is the daughter of Francis Peabody, a resident of 
Portland and a member of the Board of Directors of The AIDS 
Project. Francis appears in the video and will attend the 
premiere to answer questions from the audience. 
The 48 minute documentary explores the experiences of 
mothers and fathers, sisters and brothers, partners and friends 
who have lost or are losing someone to AIDS. These intimate 
interviews show that families, like AIDS patients themselves, 
risk rejection and isolation because of fear and ignorance 
about transmission of the disease, and experience prejudice 
due to its association with homosexuality. 
Too Little, Too Late 
The AIDS Project 
Page 2 
Victor Neufeld, Executive Producer of ABC's 20/20 called 
this production "a powerful work of high professional quality 
.. the victims of AIDS as I have never seen them protrayed 
before." 
Too Little, Too Late was made by Boston producer/director 
Micki Dickoff and is being released nationally by Fanlight 
Productions, a Boston-based distributor of independent film 
and v ideo programs . .Major fundi ng was provided by the 
American Foundation for AIDS research. Filmmaker Micki Dickoff 
will be present at the premiere, and a discussion with repre-
sentatives of The AIDS Project will follow each showing. 
"I wanted to show the human side of AIDS, beyond the stat-
istics," Dickoff says. "My hope is that when people see this 
devastating disease through the eyes of families much like their 
own, they will be moved to replace fear and prejudice with 
compassion and understanding." 
The Portland premiere of Too Little, Too Late is sponsored 
by The AIDS Project, a Portland-based organization providing 
services to persons with AIDS and their families. Proceeds 
from this event will benefit the work of The AIDS Project, and 
tickets will be available at the door or may be reserved by 
calling 774-6877. Tickets will be provided for a donation of 
from $5.00 to $25.00. 
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PLEASE MAKE NOTE OF OUR NEW MAILING ADDRESS ABOVE ........ . 
A NEW CHAPTER 
by 
Gary L. Anderson 
A new chapter in the history of the AIDS Project begins this month. 
As sane of you may already know, I have voluntarily chosen to resign as 
Executive Director of the AIDS ProJect. I have made this decision after 
careful thought and consideration. Everything seemed to be Just right for me 
to make this choice now; and so I have. 
I will continue to be an active voice and presence in the fight against 
the spread of the AIDS virus in Maine and in the development of the services 
required by persons affected by AIDS virus Infection. 
I will continue my association with the AIDS ProJect, but in a different 
guise. Instead of acting in a largely aciDlnlstrative role, I intend to 
address my personal and professional skills to the areas of policy, advocacy, 
ccmnuni ty organ! zatlon, pub I le re I at ions, and eci.lcat ion. As you are we 11 
aware, I have performed many of these functions over the past three years. As 
Executive Director, however, I was finding less and less time to do so. The 
responsibl 11 ties of the Executive Director go far beyond these tasks. Such 
responsibilities are no longer those I desire to have. 
Robert Mitchell will be assuming the position of Executive Director 
effective February 1. I hope you will lend him the same kind of support that 
I have received fran all of you. 
SPECIAL NOTE 
As featured in our January issue of this newsletter, there is an ongoing 
appeal to all PWA's and persons with ARC and HIV positive to please step 
forward and assist in the formation of a PWA Coalition in Maine. Please 
contact Bert at 775-1259 if you have any questions, comments and/or 
interest~onymity is assured. 
WHEN YOU SEE SOMEONE WITHOUT A SMILE, ~ 
GIVE THEM ONE OF YOURS ......... _ 
I 
LET'S HUG 
THERE'S A HUG TO SAY 
I LOVE YOU 
AND A HUG TO SAY GOODBYE 
THERE'S A HUG TO SAY 
HOW ARE YOU 
AND A HUG TO SAY, WE TRIED 
THERE'S A HUG TO BOND 
A FRIENDSHIP 
AND A HUG WHEN THE DAY 
IS THROUGH 
BUT THE HUG I LOVE 
IN ALL THE WORLD IS 
THE HUG I GET FROM 
YOU! 
The following article is the last in a series o f related s11bj ec ts concerning var1 011 s dr11g s 
11sed fo r the treatment o f AIDS. It is re~rinte i.l with permission from the Pl.A Coali ti on ,o f 
~ew York City. 
EDITOR'S NOTE : CORRECTION. In the January issue of the Newsletter, R. C. Morse's re port on 
Ampligen incorrectly st ates that there was a 2-5 fold increase in T4 cells in pat i ents with 
AIDS in the study. T!"le re were only 3 people with AIDS in that study and "a transient 2.5 
fold increase in T4 ce lls at 4 weeks'' was claimed by the author of The Lancet article. 
The data on changes on T4 cells on the 3 people with AIDS published in The Lancet is as 
follows: The first patien t had 21 T4 cells at entry and 24 T4 cells after 18 weeks of treat-
ment. The sec ond patient had 54 T4 cells at entry and 90 after 6 weeks of treatment . The 
third patient sta r ted with 35 T4 cells and 18 weeks after treatment there were 31 T4 cells. 
:-tr. Morse states chat his information came directly from Dupont, which manufactures Ampligen. 
ddC 
by R. C. Morse 
Dideoxycytidine, or ddC, was first synthesized in 1964. In 1984 laboratory research begun 
by Dr. Samuel Broder, associate director of NCI's Clinical Oncology Program, and his colleague, 
Dr. Hiraki Mitsuya, discovered that ddC inhibits replication of the AIDS virus in cell cul-
tures, and could be a possible treatment for AIDS. 
The NCI started a pilot trial at the end of 1986 for individuals with ARC and AIDS. So far, 
this study has enrolled a total of 20 individuals who received treatment for up to 12 weeks. 
Although results from this study suggested antiviral activity, it is still too early to make 
conclusive results. In addition, side effects different from those caused by AZT were observed. 
ddC is a chemical variation of an essential DNA component. The chemical is thought to work 
by inhibiting the normal function of "reverse transcriptase", a viral enzyme necessary for 
HIV replication, working at a critical step in the HIV replication cycle. Inhibiting this 
step may stop the spread of HIV from cell to cell . ddC seems to work in a manner similar to 
that of AZT. 
While the Federal Government holds the patent on ddC, its National Technical Information 
Service, the licensing agent for the U.S. Dept. of Health & Human Services, accepted bids 
this year from a number of leading drug manufacturers for development of the antiviral. Of 
those bids submitted, that by Hoffmann-LaRoche, Inc. of Nutley, NJ was accepted. The agree-
ment, announced on May 29th, gives Roche exclusive license to develop, and after approval, 
market ddC . 
Scientists at Roche are now working closely with the NCI and NIAID in further clinical 
trials of ddC with PWAs. Roche has no plans at this time to test ddC against or concomitantly 
with AZT, although such a test may develop in the future. Roche does not expect to be in a 
position to make even a preliminary statement about ddC's efficacy until early next year. 
NOTE: In a letter published in the September PWA Coalition Newsline, Dr. Barry Gingell 
writes: "In the vast majority of patients taking ddC for more than 8 weeks, a significant 
peripheral rieuropathy occurred. In some patients, this has been mild; but in others, it has 
been severe and required morphine for pain relief •••. Moreover, the damage done to the nerves 
has not reversed to date after discontinuing ddC •..• Because of this toxicity, the future of 
ddC is bleak." 
Naltrexone 
Naltrexone is an oral opiate antagonist originally developed by the National Institute on 
Drug Abuse and FDA-approved for the treatment of narcotics addicts. At a high dosage of about 
50 mg/day, Naltrexone works by blocking opiate receptors -- sites on cell membranes where 
opiates have their effect. If a person on Naltrexone later takes heroin or other opiate, the 
drug will not have the desired effect or expected high. Naltrexone has also been tried in 
very high doses, 200-300 mg/day, for treating obesity. 
The thinking that brought Naltrexone into consideration as a treatment for AIDS is based 
on its relationship with the endorphin system. Endorphins are produced by the pituitary gland 
and elsewhere in the body and act as the body's own natural opiates. These natural opiates 
help the body respond to stress, and are also released into the body through various forms of 
exercise, accounting for what is commonly referred to as jogger's or runner's high. 
What immunologists have since discovered is that endorphins are a major link in communica-
tion between the body's central nervous and immune systems. Every cell in the immune system 
has receptors that respond to endorphins. What initial research suggested was that endorph ins 
seem to serve as a natural up-regulator for the entire immune system. 
~ 
-
The blocking effect of low-dose Naltrexon~ wears off in a few hours , but at the same time 
the up-regulation of the immune system works di,ring the blocking period and for the rest of 
t he day as well. The drug is taken orally before sleep because the pituitary produces most 
endorphins in early morning . 
The first application of Naltrexone for AIDS was a phase one, double blind trial started 
at Downstate Medical Center in Brooklyn, NY in mid-1985 by Dr. Bernard Bihari and colleagues . 
Of 30 individuals in the trial, 20 were given a placebo, while the other 19 were treated with 
1. 75 mg/day of Naltrexone. After three months, those on the placebo were switched to Naltrexone . 
The key test of whether Naltrexone is working is not by T-cell counts, but rather a reduction 
in the abnormally high levels of alpha interferon found in PWAs. In abstracts delivered at 
last year's international conference on AIDS in Washington, Downstate reported that of the 
39 individuals treated with Naltrexone, 23 (or 60%) showed a marked decrease in alpha inter-
feron levels down to normal antiviral levels over a 12-month period, while the other 16 (40%) 
showed continued high levels of alpha interferon. Those who responded to Naltrexone treat-
ment also showed a higher survival rate over the year than the nonresponding group (83% vs. 19%) . 
However, despite these encouraging preliminary results, Dr. Bihari warns against over-
optimism. The data on Naltrexone is limited because the phase one trial involved so few indi-
viduals. But Dr. Bihari is hopeful that a phase two trial with more individuals participating 
will prove the efficacy of Naltrexone treatment. 
Since the Naltrexone study began before approval of AZT, initially none of the individuals 
involved in the Downstate study were using AZT concomitantly with Naltrexone. Since FDA ap-
proval of AZT, a number of PWAs on Naltrexone have also started AZT therapy. No interactions 
or side effects have been as yet reported when the drugs are taken concomitantly. Naltrexone 
is administered by dozens of doctors in private practice since it is already FDA-approved, 
and it is also made available on a "compassionate use" basis for PWAs as approved by the FDA. 
Pentamidine 
Pentamidine is an antiviial that is an alternate therapy from sulphur-based drugs for the 
treatment of pneumocystis carinii pneumonia (PCP), the most common life-threatening oppor-
tunistic infection in PWAs. While it can be effective against PCP, when administered intra-
venously it causes severe side effects, such as diarrhea and vomiting, as it is absorbed 
through the body's organs -- especially the kidneys and liver. 
The use of Pentamidine administered in aerosol form directly to the lungs as a prophylaxi s 
against PCP has been the subject of a continuing study at New York City's Memorial Sloan-
Kettering Cancer Center. Studies in animals first showed that aerosol Pentamidine can prevent 
PCP. At Sloan-Kettering, under Drs. Donald Armstrong, Ed Bernard, Laurel Pagel, and associ -
ates, an ongoing trial is already in phase two. 
Results from phase one were published in June in "Clinical Research". The article makes 
the point that aerosol administration delivers Pentamidine direct to the desired site of 
action, the lungs, thereby eliminating its accumulation (and therefore its side effects) in 
other organs. At Sloan-Kettering, individuals are administered Pentamidine at bi-weekly doses 
of 30 mg. u~ing a hand-held ultrasonic nebulizer. 
60 PWAs were treated for 1-11 months in phase one. No participant in the study showed a 
significant decline in pulmonary function, abnormalities in biochemical or hematologic tests, 
or chest x-ray changes attributable to aerosol Pentamidine. Nor was any detectable systemic 
absorption detected. 
Of the 60 individuals involved, two confirmed cases of PCP occurred; both PWAs had re-
ceived 5 doses of aerosol Pentamidine. No one in the study who received 6 or more doses have 
developed proven or provable PCP. The researchers say they should have seen 12-18 cases of 
PCP if the regimen had been ineffective. Based on these preliminary results, the researchers 
conclude that "aerosol Pentamidine is a well-tolerated and promising new method for PCP 
prophylaxis". 
A number of doctors in private practice are also administering aerosol Pentamidine as a 
prophylaxis against PCP. 
STATISTICS 
As of January 20, 1988, there have been 65 diagnosed cases of AIDS in 
Maine. Of the total 65 cases, 31 have died. People who have tested positi v e 
with the AIDS virus (in Maine) is now at 240 . National Data as of January 
4, 1988: diagnosed cases of AIDS 50,265. Deaths 28,149. 
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:he :allowing a r ticle i s r2p r intej with permission from :~2 
?WA Co a litio n of ~e w Yo r k City . 
[EDITOR'S NOTE: The following letter has been sent to several gay publications. It is 
provided for information purposes only.] 
To Whom It May Concern: 
It has come to our attention that several gay publications, including the New York 
Natjve, The Advocate and the Villaie Voice, are accepting advertisements from companies 
offering "egg lipids" or "egg lecithin." As founding members of the People With AIDS Health 
Group-a group formed to make egg lipids availahle to those individuals who desired to 
purchase egg hpids--we believe we have developed a body of experience which we'd like to 
share with those of your readers wishing to purchase lipids. 
The lipid "market" is changin~ rapidly. Smelling huge profits, a number of manufacturers 
and distributors of lipids are entenng the market. As a result, within the next few months 
there is likely to be a "price war." To the extent that this competition lowers the price of 
lipids, it will benefit the consumer. However, there are a number of points which potential 
purchasers of lipids should consider: . 
1. Beware of Manipulative Advenisini and False Clajms. Although there are 
theoretical reasons to believe the egg lipids may be of some benefit to People with AIDS and 
ARC, there presently exists no data conclusively demonstrating a beneficial effect for lipids in 
AIDS. Beware of any company or individual who asserts or strongly implies with authority 
that lipids are a "cure" for AIDS. 
2. Beware of any Company who wm not Ten You the Precise Chemical Analysis of the 
Ll~jds They are Selljn2: The interest in egg lipids as a potential treatment for AIDS and ARC 
is ased on studies published in Israel on a substance called AL721. The name "AL721" stands 
for "Active lipids in a Ratio of 7 to 2 to l." AL721 is a trademarked name for egg lipids in 
roughly a ratio of 7 parts neutralipids, 2 parts phosphatidylcholine and 1 part 
phosphitydalethanolamine. 
Although no one knows for. certain whether this ratio of 7:2: 1 is critical, we believe that 
it is important to come as close as possible to this ratio whenfurchasing analogues of AL721. 
Our reasoning is this: we know a httle bit about the effects o egg lipids in roughly a ratio 
of 7:2: l; at the current time, we know nothjn~ about the effects of egg lipids in significantly 
different ratios. 
Future research ma( someday prove that this 7:2:1 ratio isn't very important; that soy 
lecithin works just as wel as egg; or that it's unimportant whether you take it on a fat-free 
stomach. But until such time as these questions are resolved by research, we urge purchasers 
of lipids to insist on products which conform as closely as possiQle to a ratio of 7:2: 1. 
3. Beware of Any Company Which Does Not Guarantee that Each Lot of Lecithin is 
Tested For Potential Bacterial. Funial or Chemical Contaminants as Well as for Ratio of Lipids 
and Pho~pholipids: Several comparues are claiming that their "egg lipids" conform to a ratio 
oi 7:2: 1. Since batches of commercially produced egg lipids vary in composition, the only way 
that a company can know the precise rauo for a particular batch is if it runs several 
complicated and expensive tests. Consumers should insist upon seeing documentation for each 
Jwm purchased. We believe a number of companies are claiming that they test each batch 
when 1.0 fact they are not. Don't be fooled. Prior to purchasing, ask them to send you 
documentation--or have them send it to your doctor. 
It's also important to make sure that your e~ lipids are free from contaminants. This 
requires a series of tests and cultures which are Ulne-consuming and expensive. But you must 
insist that they be done. Egg lipids can spoil if contaminated and/ or not properly 
refrigerated. (Think of lipids as perishable, like mayonnaise.) Make sure that any lipids you 
purchase have been roperly tested for chemical or other contaminants. 
4. w · · · · • The actual 
manufacturing cost of one ·10 ( 1000 grams) of egg lipids-exclusive of packaging. importation 
and other handling costs--should be about $100. If all the recommended bacterial and 
compositional tests are performed, the price per kilo will of course be higher to recover these 
costs. But if the price is significantly more than $200, then something's wrong. Beware of 
anyone charging thousands of dollars for egg lipids. 
• • • 
JI, 
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" '.:::;;! Lioi ds " co n t. 
The PW A Health Group has publicly stated that it is our goal to get out of the business 
of "selling" lipids as soon as possible. Having delivered over a ton of egg lipids to PW As and 
PW Arcs bas been a logistic nightmare. It has been time consuming ancf expensive to pcrfonn 
the requisite tests on each ancf every lot which we've delivered. We sincerely hope that the 
companies currently entering the market make it possible for us to go out of business. But 
before we get out of the Heid business, we feel obligated to insure that the companies are 
behaving ethically and delivering the best product-one which bas been analyzed and testcd-
at the lowest cost. 
It is to be expected that increased competition among various suppliers of lipids will 
occasion wild charges bac~ and ~orth between the various supyliers .. In all l~eliho?d, various 
suppliers will attempt to d1scred1t the products of other suppliers while making claims for 
their own. The key is for consumers to become educated enough to sort through the claims 
and counterclaims of competitors. 
What will be required in the next few months is that consumers of egg lipids will have 
to become educated about what to demand from companies selling lipids. We hope that the 
information contair1ed here is helpful towards that goal. .,. _____________ _ 
V cry trul[yours, 
~,wi,y ~ ;u~ ~ It- JMiA.. chaSoel beCall;nManDd 
g,ri "-'t caUfllte ~ -,«r • • nna nu. . . SAFER 
SEX 
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I CAN BE SENSUOUS! J 
Cartoon by Michael Willhoite 
from his book of cartoons 
"Now For My Next Trick" -
Available from Alyson Publications, 
Inc. - 40 Plympton Street - Boston, 
Mass. 02118 
. THE OFFICE ON AIDS CLEARINGIOOSE 
. The _Maine Burea~ of . Health AIDS clearinghouse contains a variet of 
1nformat10~ ~or a diversity of audiences on HIV-infection and the A~ired 
~rrmun7 Deficiency Syndrome. Mat7rials include the following issues: blood 
o~ati?ns, bank~, az:d transfusions; counseling and testing; education; 
7Pidemiology; .finan~ial issues; health care and infection control; 
~nsurance, ~egislation, and law; prisons; public health; psychosocial 
issues~ patient ?are; policy and law; persons; public health· risk 
reduction; school issues; sex and sexuality; sexually transmitted di:seases• 
therapy ~d treatment; women, children and AIDS; AIDS in the work place· and 
general information. ' 
Material are .available in the form of brochures, booklets, books, video 
cassett~s an~ au~io .cassettes. A catalog will be available in the Spring of 
1988 which will indicate the exact publications, a brief description of the 
contents, and the quantity or time period in which it is available. 
By working closely ~ith the Department of Human Services Library, we 
hav7 been able to establish a small collection of books and videos that are 
available on loan, on a first come basis. 
The catalog will include materials available from both the Library and 
the Office on AIDS. 
The Office on AIDS welcomes requests for materials. 
information, contact the Office at 289-3747. 
s 
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FEB. 6 Maine Lesbian/Gay Polii:ical Alliance Annual '1eeting - Sen a to r- ::1.1 
We stern Avenue, Augusta - 12 noon to 4pm - cocktails at Som -
dinner at 6:30pm - speeches, awards, and dancing after di~ner -
contact Barb Wo od at 871-1555 for prices and reservations - PWA's 
admitted free but reservations must still be made. 
FEB. 12- Lear.1 To ~e ach About AIDS - An Instructional Symposium - Maine 
~ed i ~~ l Center - co ntact Larry Johnson at 623-8411 x5622 for 
fur~~er informa tion . 
FEB.18-20-A~SAODD'S 2nd Annual Forum On AIDS and Chemical Dependency -
The Hyatt Reg enc y - ?hoenix, Arizona - for registration, prices, 
and additional in formation, please contact area 404-458-3382. 
FEB.22-26-There will be a nightly report on AIDS on \vGME channel 13, with 
a "l ive" call in show on Friday the 26th. Please refer to your 
local TV listings for that week for proper times to be aired . 
MAR.4-6- AIDS Medicine and Miracles - What Holds Promise - Boulder, 
Colorado - please call area 303-447-8777 for further information. 
MAR.10-11-Developing AIDS Community Education Program for Family Planning 
programs - call Karen Brenner of the John Snow Institute at area 
617-482-9485 for further information . 
MAR.21-22-Interfaith Conference on AIDS and ARC - for detailed information 
contact: AIDS/ARC Conference Proceedings - c/o Shanti Project -
525 Howard Street - San Francisco, California 94105. 
SPRING 
1988 
- . Aids Prevention Education Conference Follow-Up - Maine Medica l 
Center - call 871-2131 for further information. 
JUL.20-26-The Second International Lesbian and Gay Health Conference and 
AIDS Forum - Call For Participation - Boston Park Plaza Hotel and 
Towers - To submit a proposal and for registration information 
contact NLGHF/AAPHR Programming Committee - P.O. Box 65472 -
Washington, o.c. 20035 or contact Michael Weeks at 202-797-3708 
or Greg Thomas at 202-994-4285. 
ONGOI NG CALENDAR ' 
Every Tuesday from 10:30am to 12noon at The Aids Project - 48 Deering 
Street - Portland - there is a group meeting for all PWA's PWArc, care-
givers, and family members, to share your thoughts and feelings relative 
to Aids. The meeting is conducted by Jacob Watson, M.A. Jacob is a 
psychotherapist specializing in loss and transition and is a staff member 
of the Elizabeth Kubler-Ross Center. 
Every Tuesday evening 7:00pm to 8:30pm at 29 Cushman Street - Portland -
there is a group meeting for all lovers, caregivers, friends, and family 
members only . The meeting will be conducted by Brooke Alexander, an 
Episcopal priest and pastoral counselor. Call Brooke at 772-1678 or Lucy 
Marbach at The Aids Project 774-6877 for further information. 
On the first Tuesday of every month at The Aids Project - 48 Deering St. -
Portland: 
6:00 p.m. - A-Line Staff Meeting. 
7:00 p.m. - HIV Counselor Staff Meeting. 
Support Group for Parents of Adult Gay Children will meet the 2nd Tuesday 
of every month. Please call 774-HELP for time and place. 
' O~G OI~G CALE~DAR cont. 
Support Group for Parents and Friends of Gays will meet the 4th Tuesdav 
of every month at the Pil]rim House - 9 Cleaveland St. - S!"unswick, ~te : -
Call 729-9843 for further information. 
There is now an AIDS support group in the Bangor area meeting every Thur s -
day evening. Anyone interested in the group should call 469-7343 or wri te 
EMAN - P.O.Box 2038 - Bangor, Maine 04401 
Every Frida y evening 6:00pm to 7:30pm at The Aids Project - 48 Deering 
St. - Portland - there is a sup?ort group meeting for PWA's and PWArc 
ONLY. Call 774 - 6877 for further information. 
ISPECIALI .. _ - - ... - - ------ ... -- ... -- -- ----~ 
"I wish ... oh forget it" he said, the smile fading. "You know, I regret more 
than anything else, that all the things I want to do for my son I can never do . 
I don't know how much more time I have; no one really knows. I just wish I cou ld 
do something special for my son." 
"He always wanted to go to Disneyland with me. I wish I could take him. He 
could ha VE"! "' memory connected to his father that was happy and fun." 
The above remarks were part of a lengthy conversation between Bill (not his 
real name) and Lucy Marbach of our Aids Project office. 
Bill is a 42 year old man living in Maine, who has Aids. He contracted the 
virus sharing needles during IV drug use. When Lucy and Bill met over six months 
ago, he was very ill and very scared. Scared of dying and scared of being out of 
control because of drugs and alcohol. He knew that his use of drugs and his 
having Aids was a lethal combination. 
One day last summer he completely stopped using drugs and alcohol. That was no 
easy task for a man who had been addicted for 30 years! His control of the drug 
problem has dramatically improved the quality of his life. 
Today, Bill is a changed man who has learned to explore the calm, gentle 
peaceful side of himself. He owes a great deal to the support and encouragemen t 
he has found in AA in combination with his discovery of a higher power that 
works hand in hand with his inner strength. 
Bill describes his past drug use as "chasing a dream." Today, Bill has a new 
dream. A dream of being able to share a time of laughter and love with his 8 
year old son . . He has an income of $350. per month in disability benefits; barely 
enough to survive on. 
So many good people are now asking; "What can I do to help someone with Aids?" 
This is an opportunity for you to make a difference in the quality of one per-
son's life. If you would like to help with Bill's dream, please send a contri -
bution to The Aids Project at P.O. Box 4096, Portland, Maine 04101. Please make 
a note on the check or attach a note that specifies this donation to "Disney 
Dream." Thank you. • _. • - - - -
a1>aJi&((l\JJi\f 
StrasCRIBE NOW TO THE AIDS FROJECT NEWSLETTER 
TRIS NEWSLETTER RELIES TarALI.Y ON StrasCRIPrIONS TO EXIST. WE 
ARE GRATEFUL TO THOSE WHO HAVE SUBSCRIBED, AND TO THOSE WHO 
HA VE NO?, PLEASE DO SO NOW. $10. 00 COVERS ONE ?EAR ( 12 ISSUES). 
FIE.ASE MAKE YOUR CHECK OR MONEY ORDER PAYABLE TO "THE AIIS 
FROJECT". TRANX YOU. -
----------------------------------------------------------~---NAME ___________________________________ __ 
ADDRESS _______________________________________ _ 
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